CClinicalTrials.gg
Sign In
RecruitingNCT07764081Updated Aug 13, 2026

Progression, Management, and Clinical Outcomes of Coronary Artery Aneurysms

An observational study in Coronary Artery Disease, Aneurysms and Coronary Intervention, sponsored by Nanjing First Hospital, Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Nanjing First Hospital, Nanjing Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aimed to characterize the progression and risk fators of coronary artery aneurysms, and copmpare the outcomes across different management strategies

Read the detailed description

This study aim to investigated the progression of coronary artery aneurysms (CAA) assessed by angiography, then compared the effectiveness of different management strategies, and identified risk factors associated with lesion progression and major adverse cardiovascular events.

02

Conditions studied

  • Coronary Artery Disease
  • Aneurysms
  • Coronary Intervention

Keywords

  • Coronary Artery Aneurysms
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients diagnosed with coronary artery aneurysm

Inclusion criteria

  1. Angiographically confirmed coronary artery aneurysm, defined as coronary dilation ≥1.5 times the adjacent normal reference vessel diameter.
  2. Age 18-80 years.

Exclusion criteria

Exclusion Criteria:

  1. Suboptimal image quality
  2. Incomplete clinical data, including medical history, laboratory parameters, or follow-up records.
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Coronary Artery Aneurysms

    Patients with angiographically confirmed coronary artery aneurysms, defined as coronary dilation ≥1.5 times than the adjacent reference vessel diameter,

05

What researchers measure

Primary outcomes

  1. Progression of coronary artery aneurysm

    Progression of coronary artery aneurysm assessed by serial angiography or coronary computed tomography angiography

    Time frame: 6-12 months

06

Study locations

1 of 1 sites recruiting
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
    Recruiting
07

References and documents

Publications

  • Nunez-Gil IJ, Cerrato E, Bollati M, Nombela-Franco L, Terol B, Alfonso-Rodriguez E, Camacho Freire SJ, Villablanca PA, Amat Santos IJ, de la Torre Hernandez JM, Pascual I, Liebetrau C, Camacho B, Pavani M, Albistur J, Latini RA, Varbella F, Jimenez-Diaz VA, Piraino D, Mancone M, Alfonso F, Linares JA, Rodriguez-Olivares R, Jimenez Mazuecos JM, Palazuelos Molinero J, Sanchez-Grande Flecha A, Gomez-Hospital JA, Ielasi A, Lozano I, Omede P, Bagur R, Ugo F, Medda M, Louka BF, Kala P, Escaned J, Bautista D, Feltes G, Salinas P, Alkhouli M, Macaya C, Fernandez-Ortiz A; CAAR investigators. Coronary artery aneurysms, insights from the international coronary artery aneurysm registry (CAAR). Int J Cardiol. 2020 Jan 15;299:49-55. doi: 10.1016/j.ijcard.2019.05.067. Epub 2019 Jul 19. PubMed 31378382 ↗

Individual participant data

Plan to share: No — Due to privacy and ethical limitations, the data generated and analyzed in current study are not publicly available but could be obtained from principal investigator upon the approval of ethics committee

08

Registry details

Key details

Study ID
NCT07764081
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Responsible party
Ye-fei (chief physician, Nanjing First Hospital, Nanjing Medical University) — Principal investigator
First posted
Aug 13, 2026
Start date
Jul 31, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Aug 13, 2026

Study contacts

Fei Ye, MD
Contact
doctor_ye@126.com
18951670287 ext. +86
Yi-fei Wang, MD
Contact
happywangyf2018@163.com
18852577798 ext. +86

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Coronary Artery Disease→

Other studies from this sponsor

Nanjing First Hospital, Nanjing Medical University

Start the discussion